Dental Implants Market

When China’s national dental implant tender opened in Chengdu on 11 January 2023, the average winning bid fell 55% to just over CNY 900 (about USD 133) per implant, against a previous average of CNY 5,000 (Yicai Global). That single procurement round, covering about 2.87 million implants, shows where the dental implants market is heading: more implants placed, at lower prices per implant. The dental implants market covers the titanium and zirconia fixtures placed in the jaw to anchor a crown, bridge or denture, together with the abutments, prosthetic components and guided surgery tools sold with them, counted at manufacturer realised prices. Douglas Insights values the dental implants market at USD 6.24 billion in 2025 and expects USD 11.1 billion by 2035, compounding at 5.95%. The estimate is built from the bottom up: roughly 21.5 million dental implants placed in 2025 across premium implant systems, value and challenger implant systems, abutments and prosthetic components (the zirconia used for many abutments and implant crowns is sized in our Zirconia Dental Indirect Restorations Material Market report), and guided surgery and digital planning, at an average realised manufacturer price of USD 290 per implant including associated components. Implants placed grow 6.8% a year, while realised price per implant falls 0.8% a year as value brands and government procurement in China pressure prices. This study sits within our dental care coverage and follows the published Douglas Insights methodology.

What did China’s 2023 implant tender do to dental implant prices and volumes?

China’s January 2023 dental implant tender cut the average winning price by 55%, to just over CNY 900 per implant, and bundled it with caps on dentists’ procedure fees. The round bought about 2.87 million implants, roughly 72% of China’s annual total, for nearly 18,000 medical institutions, and lower prices reached patients from as early as late March 2023.

The National Healthcare Security Administration ran the round as part of its volume based procurement (VBP) programme: manufacturers bid for guaranteed public-sector volume by offering steep price reductions (Yicai Global). Of 55 bidders, 39 won places. Premium brands, including Straumann, Dentsply Sirona and Nobel Biocare, bid about CNY 1,850 (USD 274), while the lowest bid, from a domestic maker, was CNY 548. The 2.87 million implants in the round imply about 4.0 million implants a year placed in China, about 18.5% of the 21.5 million placed worldwide in 2025 in our model.

Treatment surged as the procedure became affordable to many more people, and domestic Chinese manufacturers gained share. The lesson for the dental implants market is that implant prices are set by purchasing structures as much as by technology, and that lower prices unlock latent demand. The next cycle, VBP 2.0, is already moving the market: Straumann reported on 18 February 2026 that its Asia Pacific organic revenue fell 12.8% in the fourth quarter of 2025, mainly because Chinese patient flow slowed while the delayed VBP 2.0 process was pending (Straumann Group FY2025 release).

Which implant parts, materials and buyers count toward the USD 6.24 billion dental implants total?

The USD 6.24 billion dental implants total counts four product categories, titanium and zirconia implants, and three buyer groups: independent practices, dental service organisations, and hospitals and public clinics. Crowns, bridges, dental equipment, separately sold bone grafts and dentists’ fees sit outside it, and every figure is measured at manufacturer realised price.

Premium implant systems are implants from established brands with long clinical records, proprietary surfaces and broad product ranges. Value and challenger implant systems are lower-priced implants from newer and regional manufacturers. Abutments and prosthetic components are the connecting parts that attach the crown or bridge to the implant. Guided surgery and digital planning covers surgical guides, planning software and workflow tools sold by implant manufacturers.

Titanium implants account for most of the 21.5 million placements, because titanium and its alloys carry the deepest evidence base for bone integration. Zirconia implants, usually one-piece ceramic posts chosen for metal-free or front-tooth cases, are a small niche counted inside the premium and value categories rather than as a separate line. Hospitals and public clinics matter most in China, where the 2023 tender supplied nearly 18,000 medical institutions; in Europe and North America implants are placed mainly in independent practices and dental service organisations. Dental crowns and bridges and their materials, dental equipment such as imaging and chairs covered in our separate dental equipment coverage, bone graft materials sold separately and the fees charged by dentists sit outside the boundary.

What are screwless dental implants?

Screwless dental implants hold the abutment in place by friction instead of an abutment screw: a tapered post is tapped into a matching conical socket so the two parts cold-weld together, a design usually called a locking taper. Bicon’s short, plateaued implants are the best known locking-taper system, and one-piece implants are screwless for the same reason.

The attraction is that the most common mechanical failure in implant dentistry, a loosened or fractured abutment screw, cannot occur, and there is no screw channel to hide under the crown, which matters on front teeth. The trade-offs are that a seated taper is harder to retrieve, the component range is narrower than the modular screw-retained systems that dominate the 21.5 million implants placed in 2025, and the technique differs enough that most dentists place one system or the other. Screwless designs sit inside the premium and value implant system categories in this model rather than forming a segment of their own.

Why are dental implants splitting into a premium tier at USD 2.62 billion and a value tier growing 6.81% a year?

Dental implants are splitting into two tiers because many dentists will trade premium brands’ clinical record for a much lower price. Premium systems earned USD 2.62 billion in 2025 but grow 4.21% a year, while value and challenger systems grow 6.81% from USD 2.12 billion and overtake premium systems in 2034.

The price gap is wide. In China’s 2023 tender, premium brands bid about CNY 1,850 per implant while domestic makers bid as low as CNY 548, a gap of more than three to one (Yicai Global). Premium implant companies built their positions on decades of clinical research, bone-integrating surfaces and education programmes. Value makers from South Korea, Israel, Europe and increasingly China now offer similar designs, and many have built large volumes. Dental service organisations, groups of practices that buy centrally, add buying power and push for lower prices.

Premium manufacturers answer by owning value brands. Straumann owns Neodent and sells the iEXCEL value system, which passed one million implants sold in 2025 (Straumann Group). This tiering is why realised price per dental implant falls 0.8% a year even as revenue grows 5.95%.

Why will dentists place 41.5 million dental implants a year by 2035?

Dentists will place about 41.5 million dental implants a year by 2035, up from 21.5 million in 2025, because implant placements grow 6.8% a year. Four drivers carry that growth: ageing and tooth loss, cheaper implants, digital workflows that let more general dentists place them, and dental service organisations that train and equip those dentists.

Ageing and tooth loss set the base. Older adults have lost more teeth, and implants increasingly replace dentures and bridges as the first choice for a missing tooth. Each 1-point change in the 6.8% placement rate moves the 2035 dental implants figure by about USD 1.03 billion, which is why the placement rate, not price, is the forecast’s main sensitivity. Preventive spending that delays tooth loss is sized in our Electric Toothbrush Market report.

Affordability is the fastest-moving driver. China’s 55% price cut in 2023 unlocked treatment for patients who could not pay CNY 5,000 for an implant, and the round alone covered about 2.87 million implants. Value systems that cost a fraction of premium ones bring the same effect to private markets: Straumann’s iEXCEL value system sold more than one million implants in 2025, and value and challenger systems add USD 1.98 billion of revenue by 2035, more than any other category.

Digital dentistry makes placement more predictable. Intraoral scanning, planning software and guided surgery shorten chair time and reduce placement errors, encouraging general dentists, not only specialists, to place implants. Guided surgery and digital planning grow 9.51% a year, from USD 498.8 million to USD 1.24 billion, the fastest rate of any category, and each guided case adds licence or per-case revenue on top of the implant itself.

Dental service organisations and training widen capacity. Group practices buy centrally, train associates to place implants and standardise on one or two systems, which lifts volume for the brands they choose. Their buying power is also one reason the price per implant falls 0.8% a year, so this driver adds volume and subtracts price at the same time.

What holds dental implant revenue to 5.95% a year when placements grow 6.8%?

Dental implant revenue grows 5.95% a year rather than 6.8% because the realised price per implant falls 0.8% a year. Price pressure from tenders and value brands is the main restraint; out-of-pocket cost and clinical complications are the other two, and together they keep some patients on dentures or bridges.

Price pressure is the largest restraint. China’s 2023 tender cut average prices by 55%, and the price compression scenario, in which procurement spreads to more countries, sets the price leg at minus 3.0% a year, taking the 2035 dental implants figure to about USD 9.39 billion instead of USD 11.1 billion. Straumann’s 12.8% organic fall in Asia Pacific revenue in the fourth quarter of 2025, linked to the delayed VBP 2.0 round, shows that even the expectation of a new tender slows orders.

Cost and reimbursement are the second restraint. Implants are paid largely out of pocket in most private markets, are often only partly covered by insurers and public systems, and demand falls when household budgets tighten. In China, a CNY 5,000 implant before the tender was beyond many patients, which is why the price cut released so much demand.

Clinical complications are the third. Implant failure and peri-implantitis, an inflammatory condition around implants that daily brushes and water flossers from the Interdental Cleaning Products Market help prevent, deter some patients, and the need for skilled placement limits adoption among dentists who do not place implants routinely.

Which dental implants segment carries the revenue?

Premium implant systems carry the most dental implants revenue, 42% of 2025 value or USD 2.62 billion, because their prices are several times those of value implants. They grow slowest, at 4.21% a year to USD 3.95 billion, and value and challenger systems overtake them as the largest category in 2034.

Premium systems defend price rather than volume. Value and challenger systems reach USD 4.10 billion at 6.81% a year. Abutments and prosthetic components rise from USD 997.6 million to USD 1.82 billion at 6.21%, since every implant placed still needs a connection to the crown and more of those connections are custom milled. Guided surgery and digital planning reach USD 1.24 billion.

Which dental implants segment grows fastest?

Guided surgery and digital planning grow fastest in revenue, at 9.51% a year, from USD 498.8 million in 2025 to USD 1.24 billion in 2035. It is the only category whose price leg is not falling: planning software, surgical guides and workflow tools are priced as licences and per-case services that procurement tenders do not touch.

Implants themselves lose 0.8% of realised price a year to value brands and tenders. Value and challenger implant systems are the fastest of the three hardware categories at 6.81%, and because they start from a much larger base they add USD 1.98 billion of revenue against USD 738.3 million from guided surgery, which is why the volume story and the growth-rate story point at different segments on this page. Premium implant systems grow slowest at 4.21% a year.

Where are dental implants placed, and why does Asia Pacific grow 7.1% a year?

Europe places the most dental implants by value, 34% of 2025 revenue or USD 2.12 billion, with high implant use in Germany, Italy and Spain. Asia Pacific grows fastest at 7.1% a year to USD 3.45 billion, driven by rising volumes in China after the 2023 tender and very high implant use in South Korea.

North America holds 28% of dental implants value and grows 5.4% a year, driven by ageing patients, dental service organisations and cosmetic demand. Asia Pacific also holds 28% in 2025 and passes North America from 2026, adding USD 1.71 billion of revenue, more than any other region; growth in Japan, India and Southeast Asia adds to China and South Korea. Latin America grows 6.4% a year, led by Brazil; Straumann’s own Latin American revenue grew 18.3% organically in 2025. Six regional models sum to the global figure, with country tables in the Excel model.

Which implant makers win premium dentists, and which win China’s procurement tenders?

Straumann leads the dental implants market with both premium and value brands, reporting CHF 2.61 billion of group revenue for 2025 at 8.9% organic growth. Nobel Biocare, part of Envista, Dentsply Sirona and ZimVie supply premium implants, while Korean and Chinese makers win on price, including in China’s tenders.

Straumann’s group revenue, which also includes orthodontic aligners and biomaterials, rose 8.9% organically in 2025, with EMEA at CHF 1.08 billion, North America at CHF 687.7 million and Asia Pacific at CHF 599.7 million (Straumann Group FY2025 release). Its Neodent and iEXCEL brands serve the value tier. Because the group figure mixes implants with other lines, this page does not yet publish a leader share for dental implants alone.

Premium brands still won places in China’s 2023 round, at bids near CNY 1,850, but domestic Chinese makers bid as low as CNY 548 and gained share in public hospitals. Osstem Implant of South Korea, taken private and among the largest makers by volume, together with Dentium and MegaGen, compete strongly on value across Asia and Europe. Regional manufacturers in Europe, Israel and China fill the rest of the value tier. The competitive chapter profiles each maker’s brands, price positioning, product range, digital capability and regional presence.

What does a dental implant cost the dentist, from the USD 290 average to China’s tender bids?

A dental implant costs the dentist USD 290 on average in 2025, the realised manufacturer price including associated components. Prices vary widely: in China’s 2023 tender the average winning bid was about USD 133, premium brands bid about USD 274, and Western premium list prices sit several times higher.

Implants are often sold with abutments and components as systems, and manufacturers add bundles, education and digital services. Dental service organisations negotiate volume pricing. Because the mix shifts toward value implants and tenders lower prices in large markets, the average realised price per dental implant falls from USD 290 in 2025 to about USD 287.7 in 2026 and keeps falling 0.8% a year, even as premium brands hold pricing in their own segment. The pricing chapter publishes price bands by tier and region.

Would wider procurement or premium pricing move dental implants away from USD 11.1 billion in 2035?

Wider procurement would cut the 2035 dental implants figure to about USD 9.39 billion, and premium pricing would lift it past USD 14.0 billion, around a USD 11.1 billion base case. The spread depends mainly on whether tenders like China’s January 2023 round spread to other public systems.

The base case carries 6.8% growth in implants placed and a 0.8% annual price decline for a 5.95% revenue CAGR. The price-compression scenario, in which procurement spreads and value brands take more share, sets the legs at 7.4% and minus 3.0%, with more implants but lower revenue per implant. The premium-resilience scenario, in which demand grows strongly and premium brands hold pricing through digital differentiation, sets them at 7.6% and plus 0.8%. Each 1-point change in implant growth moves the 2035 figure by about USD 1.03 billion.

How do EU device rules, China’s tenders and insurance cover shape dental implant prices?

Three layers of rules shape dental implant prices: device regulation sets the cost of reaching the market, procurement policy such as China’s 2023 tender sets the price in public systems, and insurance cover sets how much patients pay. China’s tender alone cut the average price by 55%.

Medical device regulation comes first: dental implants are regulated medical devices that need approval, with requirements for materials, biocompatibility and clinical evidence, and the stricter EU Medical Device Regulation 2017/745 has raised compliance costs for smaller makers. Procurement and pricing policy is second: China’s volume based procurement and its caps on procedure fees act directly on implant prices and volumes. Reimbursement is third: whether public systems and private insurers cover implants shapes patient demand. The regulatory chapter maps these requirements by jurisdiction.

Will volume based procurement spread beyond China?

Volume based procurement for dental implants is likely to spread only partly beyond China, because most Western implants are paid privately. The base case assumes moderate spread and a 0.8% annual price decline; the price compression scenario, at minus 3.0% a year, captures faster and wider adoption.

Governments that want to widen access to dental care while controlling costs may copy the China model, which bought 2.87 million implants in one round, and some countries in Asia have explored centralised purchasing of medical devices. But in many Western markets dental implants are paid largely by patients, so governments have little leverage, and care is delivered through independent practices rather than public hospitals. The most likely outcome is that tender-driven price cuts stay concentrated in markets with strong public purchasing, while private markets see gradual price pressure from value brands and dental service organisations.

Douglas Exclusive: the price and volume elasticity model

The price and volume elasticity model is a Douglas Insights model, not an observed register. It is built on the six regional models and four category price legs used in this report and calibrated on one observed price shock: China’s 2023 tender, where a 55% price cut covered about 2.87 million implants for nearly 18,000 medical institutions.

By market, it links implant prices to treatment volumes, the effect of procurement programmes, the share of premium and value implants, and patient affordability, converting demographic and pricing assumptions into implant volumes and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The dental implants model is built bottom-up from implants placed: about 21.5 million implants in 2025 times USD 290 average realised manufacturer price equals USD 6.24 billion. Six regional models sum to that global total, and four categories carry their own growth rates that sum exactly to USD 11.1 billion in 2035.

Inputs are implant procedure volumes by region, premium and value mix, procurement effects, components per implant, and realised prices from company disclosures and procurement data. Two cross-checks anchor the volume leg: China’s 2023 round of 2.87 million implants, 72% of the national annual total, implies about 4.0 million Chinese implants a year, 18.5% of our global count; and the 2035 figure of about 41.5 million implants follows from 21.5 million growing 6.8% a year. Crowns and bridges, dental equipment, separately sold bone grafts and dentists’ fees are excluded. Every figure carries a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.

Sources

1. Yicai Global Dental implant prices drop 55% after China adds them to bulk-buying program (2023)
2. Straumann Group Straumann Group full-year 2025 results (2026)
3. EUR-Lex Regulation (EU) 2017/745 on medical devices (2017)